Home » Stocks » ISEE

IVERIC bio, Inc. (ISEE)

Stock Price: $6.87 USD -0.17 (-2.41%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $6.83 -0.04 (-0.58%) May 7, 4:58 PM
Market Cap 646.52M
Revenue (ttm) n/a
Net Income (ttm) -96.27M
Shares Out 93.31M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.87
Previous Close $7.04
Change ($) -0.17
Change (%) -2.41%
Day's Open 7.00
Day's Range 6.84 - 7.10
Day's Volume 736,739
52-Week Range 3.56 - 7.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to four newly hired, non-executive employees.

4 days ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021.

1 week ago - Business Wire

ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021

Other stocks mentioned: ARR, GMDA, LIQT, LMB
1 week ago - Zacks Investment Research

EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021

Other stocks mentioned: EXTN, OR, PSXP, QIWI
2 weeks ago - Zacks Investment Research

JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021

Other stocks mentioned: BUD, EURN, JOBS, KL
1 month ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--Iveric Bio today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee.

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio granted non-statutory stock options to purchase an aggregate of 41,500 shares of common stock to 2 newly hired, non-executive employees.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.

2 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.

4 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company's common stock.

5 months ago - Business Wire

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended September 30, 2020 and provided a general business update.

6 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced today that the Company will participate in upcoming virtual investor conferences in November.

6 months ago - Business Wire

Timothy P. Lynch's Stonepine Capital is a life science-focused hedge fund that seeks to utilize its industry experience to uncover undervalued and under-the-radar health companies. The fund takes a long...

Other stocks mentioned: CTIC, CERC, LGND
6 months ago - Insider Monkey

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its third quarter 2020 financial and operating results on Monday, November 2, 2020.

6 months ago - Business Wire

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that the Company will participate in the two upcoming virtual investor conferences and a retina showcase conference in September.

8 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio granted two newly hired, non-executive employees a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.

8 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC announced that the positive Phase 3 results from its GATHER1 clinical trial with Zimura® were published in Ophthalmology®.

8 months ago - Business Wire

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced the financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update.

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced Pravin Dugel, MD will present an overview of the Company at the Wedbush PacGrow Healthcare Virtual Conference on Aug. 12, 2020.

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio today announced that it will report its second quarter 2020 financial and operating results on Wednesday, August 5, 2020.

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced the election of Mark S. Blumenkranz, M.D.

9 months ago - Business Wire

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

10 months ago - Zacks Investment Research

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: RUBY, ZYNE
10 months ago - Seeking Alpha

Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News

10 months ago - Seeking Alpha

An upsized public offering has investors increasingly confident about its prospects.

10 months ago - The Motley Fool

Shares of New York-based biopharma IVERIC bio Inc (NASDAQ: ISEE) were advancing strongly Monday morning on the back of a positive clinical readout.

10 months ago - Benzinga

NEW YORK, June 15, 2020 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive 18 month results from the Company's first Phase 3 clinical trial (OPH2003) for Zimura® (avacincaptad pego...

10 months ago - PRNewsWire

IVERIC bio (ISEE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 13th

Other stocks mentioned: IDCC, MRSN, SLDB
11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 12th

Other stocks mentioned: CHGG, CLLS, HEAR
11 months ago - Zacks Investment Research

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Iveric bio: Much More Upside Ahead

1 year ago - Seeking Alpha

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...

Other stocks mentioned: CDMO, ENDP, IGMS, ILMN, KOD, MYL, NVCN ...
1 year ago - 24/7 Wall Street

Iveric Bio Inc’s (NASDAQ: ISEE) lead asset, Zimura, could begin a pivotal clinical study in the geographic atrophy market in the quarter, according to Wedbush.

1 year ago - Benzinga

Although talking about stocks to sell typically elicits anger and negative emotions, this list is all about protecting your interests.

Other stocks mentioned: CLDR, DTSS, EROS, FCEL, MCF, SSI
1 year ago - InvestorPlace

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, CNST, DRRX, EVER, KOD, PRVB ...
1 year ago - The Motley Fool

IVERIC bio: Promising Data In GA, Valuation Still Cheap With Multiple Catalysts In 2020

1 year ago - Seeking Alpha

IVERIC bio (ISEE) reported earnings 30 days ago. What's next for the stock?

1 year ago - Zacks Investment Research

IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.

1 year ago - Zacks Investment Research

Iveric Bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ISEE

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Glenn Sblendorio
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
ISEE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IVERIC bio stock is "Strong Buy." The 12-month stock price forecast is 13.33, which is an increase of 94.03% from the latest price.

Price Target
$13.33
(94.03% upside)
Analyst Consensus: Strong Buy